It's always incredible for a company developing a new innovation in an existing field when its tech yields satisfying results. Recent news of the Kite Pharma (NASDAQ: KITE) acquisition by Gilead Sciences (NASDAQ: GILD) for close to $12 billion and the general rise of the KITE stock even prior to the acquisition - from $87.8 in mid-June all the way to over $179 yesterday - has been thrilling to watch. To say the
Antonio's Perspective Sangamo Therapeutics Inc (NASDAQ:SGMO) jumped 75 cents, or 7.85%, Friday to close at 10.25, just slightly below its key resistance at 10.50. A break above this level could move the stock significantly higher on the way to targets of 11.30 (R2) and then 12.10. Initial stop loss is 9.12 (EMA9). Looking at the technical chart, daily technical indicators are turning bullish. MACD is rising above its signal line in positive
bluebird bio Inc (NASDAQ:BLUE) broke out to a new 52-week high yesterday, accompanied by a good volume suggesting higher levels. This biotech stock has been in a nice uptrend for the last seven months and technically looks very strong with both 50-day and 200-day exponential moving averages going up, while %K line is on top of %D line and MACD rising. BLUE is now on the overbought level, so this
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) caught my eye last week when price broke the $7 resistance area with a strong momentum impulse. Price seems to be forming now a potential bullish "flag" consolidation formation. If this pattern materializes, the next move should be to the upside, because prices generally exit "flags" moving in the same direction they were moving when they entered them. (more…)
After a strong up-move in February, the stock (NYSE:NVS) is consolidating in the last four weeks in a bullish flag pattern above all major EMAs. Any break and close above the recent pivot high of 76.19 will reinstate the bullish trend. An expected upward breakout can take the stock to a target of 78. Daily technical indicators are looking Bullish. (more…)
